New research reveals that people who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional lifestyle regimens.
Findings released in a leading medical journal points out that while obese people often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be aware of the potential of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to starting weight in about a year and a half.
Analyzing Therapies
The study, which reviewed 37 of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists note that people who lose weight through dieting typically experience a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Quick Regain
Nutrition scientists believe the mechanism of the injections is key to understanding the accelerated weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
The NHS recommend the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy should be considered long-term.
This view is supported by pharmaceutical companies, who state that the results "highlight the long-term character of obesity," akin to managing diseases like hypertension.
User Experiences
Users who have discontinued the jabs describe a sudden return of cravings.
"It was like something flipping and I was suddenly extremely hungry," recalled an individual.
This difficulty is worsened if patients have not established sustainable dietary or behavioural changes during therapy.
Widespread Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is more common among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and long-term success likely depends on integrated lifestyle support.
